Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 4 1

Status

Not yet recruiting 2Recruiting 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1Gastrointestinal 1

Conditions

Carcinoma, Hepatocellular 11Stomach Neoplasms 10Carcinoma, Non-Small-Cell Lung 5Rectal Neoplasms 3Esophageal Squamous Cell Carcinoma 3Recurrence 2Nasopharyngeal Carcinoma 2Colorectal Neoplasms 2Colonic Neoplasms 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Turcot syndrome 1Thyroid Neoplasms 1Squamous Non-Small Cell Lung Cancer SqNSCLC 1Spinocerebellar Degenerations 1Small Cell Lung Carcinoma 1Resectable Non-small Cell Lung Cancer 1Rare Tumour 1Pancreatic Neoplasms 1Pancreatic Cancer Resectable 1Pancreatic Cancer Metastatic 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, Large B-Cell, Diffuse 1Lung Neoplasms 1Locally Advanced Non-Small Cell Lung Cancer 1Liver Neoplasms 1Hodgkin Disease 1HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma 1Esophageal Neoplasms 1

Interventions

Cyclophosphamide 6fludarabine 5toripalimab 3Paclitaxel 3Etoposide 3Carboplatin 3Bevacizumab 3zimberelimab 2tislelizumab 2sintilimab 2glumetinib 2Vincristine 2Temozolomide 2Platinum 2Immune Checkpoint Inhibitors 2Hepatectomy 2Gemcitabine 2Drug Therapy 2Docetaxel 2Cisplatin 2Capecitabine 2venetoclax 1relmacabtagene autoleucel 1osimertinib 1lenvatinib 1irinotecan sucrosofate 1glofitamab 1gallium maltolate 1fludarabine phosphate 1eribulin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Recurrence × sintilimab × Clear all
NCT07077798 2025-07-22

Adjuvant Sintilimab Plus Lenvatinib for HCC Characterized With VETC Following Liver Resection

Tongji Hospital

Phase NA Not yet recruiting
234 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Recurrence

NCT06761911 2025-01-07

BV in the Treatment of Relapsed/refractory Hodgkin Lymphoma

Dalian Medical University

Phase 4 Not yet recruiting
100 enrolled
Lymphoid

Hodgkin Disease, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡